Cordaflex analogs instructions for use. Cordaflex - a medicine for the treatment of cardiovascular disorders

Coated tablets contain 10 mg nifedipine in each as active substance. For excipients: polyvinyl butyral in an amount of 0.7 mg; talc (1 mg); 0.3 mg magnesium stearate ; 4 mg hydroxypropylcellulose ; lactose monohydrate (15 mg); croscarmellose sodium (13 mg); microcellulose (46 mg). The shell consists of hypromellose - 2.63 mg; titanium dioxide C.I. 77891 - 0.82 mg; yellow iron oxide - 0.3 mg and magnesium stearate - 0.25 mg.

Long-acting tablets with film-coated contain the same active substance, but in a dose of 20 mg. Each of them contains the following substances as auxiliary substances: microcellulose (99 mg); lactose monohydrate (30 mg); croscarmellose sodium (26 mg); copolymers of methyl methacrylate and ethyl methacrylate in a ratio of 1:2 (1.9 mg); talc (2 mg); magnesium stearate (0.6 mg); hyprolose (0.5 mg). The film casing is made of hypromellose - 5.26 mg; titanium dioxide - 1.64 mg; red iron oxide - 0.6 mg; magnesium stearate - 0.5 mg.

Release form

There are two options for the release form of the drug:

  • Coated tablets, weighing 10 mg. Every 100 tablets are placed in a brown glass bottle. The bottles are packed individually in cardboard boxes.
  • Film-coated tablets, having a prolonged action. Each tablet weighs 20 mg. Place 30 or 60 tablets in brown glass bottles. The bottles must be sealed with polyethylene caps that have a first-opening control. The bottle is packed in a cardboard box.

pharmachologic effect

Contraindications

Contraindications are:

  • intolerance nifedipine , other derivatives 1,4-dihydropyridine , additional components included in the tablets;
  • arterial hypotension ;
  • Not stable angina ;
  • the presence at the moment or very recently of acute, pronounced aortic stenosis ;
  • idiopathic sub aortic stenosis ;
  • chronic heart failure during the period of decompensation;
  • childhood.

It is prescribed with extreme caution to elderly patients, those with impaired renal function, and patients.

Side effects

Cordaflex is usually well tolerated. Side effects appear rarely, more often at the beginning of treatment (then they may become weaker or disappear).

There are such side effects:

  • On the heart and blood vessels: lowering blood pressure, hyperemia face and torso, swelling in the limbs , acceleration heart rate, paradoxical angina attack , development acute heart failure .
  • On nervous system : increased fatigue , emotional lability , sleep disorders, headache, .
  • On the gastrointestinal tract: occurrence, nausea , vomit , stool disorders, dryness or inflammation of the oral mucosa, intrahepatic cholestasis , as well as increased activity of certain liver enzymes.
  • On the circulatory system: thrombocytopenia , leukopenia , anemia .
  • On urinary system : increased daily diuresis, decreased renal function.

There may be allergic reactions as , exanthema , .

Instructions for use of Cordaflex (Method and dosage)

The drug is taken orally. 10 mg film-coated tablets are swallowed whole before meals with water.

The dosage is set individually, as it very much depends on the severity of the disease, the type of disease and the body’s response to the therapy. Start with 1 tablet (10 mg) 3 times a day. There should be at least 2 hours between doses of the drug. Maximum dose per day - 40 mg.

Long-acting film-coated tablets are swallowed whole and washed down with water. In this case, the initial dose is 1 tablet 2 times a day. In any case, the daily dose is divided into 2 doses, between which a 12-hour interval must be observed.

According to the instructions for use of Cordaflex, discontinuation of the drug should be carried out gradually.

Overdose

In case of overdose nifedipine the following consequences may occur:

  • arterial hypotension ;
  • pain behind the sternum (like an attack angina pectoris );
  • loss of consciousness;
  • collapse ;
  • ventricular or nodular extrasystole ;
  • bradycardia .

Interaction

Cordaflex should not be administered with alcohol-containing medications.

Possible development orthostatic hypotension when used with methyldopa , , and also with And octadine .

Cimetidine ,


Analogues of the drug Cordaflex are presented, in accordance with medical terminology, called “synonyms” - drugs that are interchangeable in their effects on the body, containing one or more identical active ingredients. When selecting synonyms, consider not only their cost, but also the country of production and the reputation of the manufacturer.

Description of the drug

Cordaflex- Selective blocker of slow calcium channels, 1.4-dihydropyridine derivative. Has antihypertensive and antianginal effects.

Nifedipine reduces the flow of extracellular calcium ions into cardiomyocytes and smooth muscle cells of the coronary and peripheral arteries. In therapeutic doses, it normalizes the transmembrane current of calcium ions, disturbed by a number of pathological conditions, especially when arterial hypertension. Reduces spasm and dilates coronary and peripheral arterial vessels, reduces total peripheral resistance, reduces afterload and myocardial oxygen demand. At the same time, it improves blood supply to ischemic areas of the myocardium without the development of “steal” syndrome, and also increases the number of functioning collaterals.

Nifedipine has virtually no effect on the sinoatrial and atrioventricular nodes and does not have an antiarrhythmic effect. Does not affect the tone of the veins. Nifedipine increases renal blood flow, causing moderate natriuresis. IN high doses inhibits the release of calcium ions from intracellular stores. Reduces the number of functioning calcium channels without affecting the time of their activation, inactivation and recovery.

List of analogues

Note! The list contains synonyms Cordaflex having similar composition, so you can choose a replacement yourself, taking into account the form and dose of the medicine prescribed by your doctor. Give preference to manufacturers from the USA, Japan, Western Europe, as well as well-known companies from of Eastern Europe: KRKA, Gedeon Richter, Actavis, Aegis, Lek, Hexal, Teva, Zentiva.


Release form(by popularity)price, rub.
20 mg tab N30 (Egis Pharmaceutical Plant JSC (Hungary)94.80
10 mg tab N100 (Egis Pharmaceutical Plant JSC (Hungary)94
20 mg No. 30 tab (Egis Pharmaceutical Plant OJSC (Hungary)100
20 mg No. 60 tab (Egis Pharmaceutical Plant JSC (Hungary)128.50
Bottles 0.01%, 50 ml679
20 mg No. 30 tab prolong.p/pl.o (Torrent Pharmaceuticals Ltd (India)64.90
20 mg tab N100 (TORRENT (India)158.40
Tab 10mg N50 (Polpharma Pharmaceutical Plant (Poland)12
40 mg tab N30 (Egis Pharmaceutical Plant JSC (Hungary)252.60
HL 40 mg tab N20 (KRKA, Novo Mesto (Slovenia)171.10
20 mg tab N30 (KRKA, Novo Mesto (Slovenia)86.60
10 mg No. 50 tab (AVD.pharma GmbH / Pliva Hrvatska (Croatia)72.70
20 mg No. 30 tab prolong. p/pl.o (AVD.pharma GmbH / Pliva Hrvatska (Croatia)112.80
20 mg No. 50 tab (AVD.pharma GmbH / Pliva Hrvatska (Croatia)157.30
40mg tablet p/o N20 (AVD.pharma GmbH and Co.KG (Germany)94.60
40mg tab N50 (AVD.pharma GmbH and Co.KG (Germany)327
Tablet p/o 10 mg N50 Ozone (Ozone LLC (Russia)29.50
10mg No. 50 tab Obolenskoye...4478 (Obolenskoye FP CJSC (Russia)38.70
Tab 60mg N30 (Lek d.d. (Slovenia)335.90
30 mg No. 28 tab (Bayer Pharma AG (Germany)183.50
Tab with control high. 30 mg N28 (Bayer Healthcare AG (Germany)196.70
60 mg No. 28 tab (Bayer Pharma AG (Germany)311
60 mg No. 28 tab (Bayer Healthcare AG (Germany)325.20
10mg No. 50 tab Zdorovye Banka (Zdorovye FC LLC (Ukraine)24.40

Reviews

Below are the results of surveys of site visitors about the medicine Cordaflex. They reflect the personal feelings of the respondents and cannot be used as official recommendation when treated with this drug. We strongly recommend that you contact a qualified medical specialist to select a personal course of treatment.

Visitor survey results

Four visitors reported effectiveness


Your answer about side effects »

Two visitors reported cost estimates

Participants%
Not expensive2 100.0%

Your answer about the cost estimate »

Seven visitors reported frequency of intake per day

How often should I take Cordaflex?
Most respondents most often take this drug 2 times a day. The report shows how often other survey participants take this drug.
Your answer about dosage »

One visitor reported an expiration date

How long does it take to take Cordaflex to feel an improvement in the patient’s condition?
In most cases, survey participants felt an improvement in their condition after 3 days. But this may not correspond to the period after which you will begin to improve. Check with your doctor for how long you need to take this medicine. The table below shows the results of the survey on the initiation of effective action.
Participants%
3 days1 100.0%

Your answer about the start date »

Two visitors reported reception times

When is the best time to take Cordaflex: on an empty stomach, before, after or during meals?
Site users most often report that they take this medication with food. However, your doctor may recommend a different time for you. The report shows when the remaining patients surveyed take their medication.
Your answer about the appointment time »

37 visitors reported the patient's age


Your answer about the patient's age »

Visitor reviews


There are no reviews

Official instructions for use

There are contraindications! Read the instructions before use

NIFEDIPINE

Registration number:


Tradename: Cordaflex
International unpatented name: Cordaflex

Dosage form:

dragee
Compound
1 tablet contains 10 mg of the active substance - nifedipine.
Excipients: milk sugar, wheat starch, cellulose
microcrystalline, talc, gelatin, magnesium stearate, sugar coating.
Description
Dragee of the correct shape, yellow color; at the fracture the core is yellow, fine-grained in structure.

Pharmacotherapeutic group:

blocker of “slow” calcium channels.
ATX code: C08CA05.

Pharmacological properties

Pharmacodynamics
Cordaflex is a selective blocker of “slow calcium ropes”, a derivative of 1,4-dihydropyridine. Has antianginal and antihypertensive effects. Reduces the flow of extracellular calcium ions into cardiomyocytes and smooth muscle cells of the coronary and peripheral arteries.
Reduces spasm and dilates coronary and peripheral (mainly arterial) vessels, reduces arterial pressure, total peripheral vascular resistance, reduces afterload and myocardial oxygen demand. Increases coronary blood flow. The negative chrono-, dromo- and inotropic effects are overlapped by reflex activation of the sympathoadrenal system in response to peripheral vasodilation. Increases renal blood flow, causes moderate natriuresis. The onset time of the clinical effect is 20 minutes, the duration of the clinical effect is 4-6 hours.
Pharmacokinetics
Cordaflex is quickly and almost completely (more than 90%) absorbed from gastrointestinal tract. After oral administration, its bioavailability is 40-60%. Eating increases bioavailability. Has a “first pass” effect through the liver. Maximum concentration in blood plasma is observed after 1-3 hours and is 65 ng/ml. Penetrates the blood-brain and placental barrier and is excreted from breast milk. Communication with blood plasma proteins - 90%. Completely metabolized in the liver. Excreted by the kidneys in the form of inactive metabolites (70-80% of the dose taken). The half-life is 2-4 hours. There is no cumulative effect. Chronic renal failure, hemodialysis and peritoneal dialysis do not affect pharmacokinetics. At long-term use(within 2-3 months) tolerance to the action of the drug develops.

Indications for use

  • coronary heart disease - angina pectoris and rest (including variant);
  • arterial hypertension (as monotherapy or in combination with other antihypertensive drugs).
  • Contraindications

  • increased sensitivity to nifedipine and other dihydropyridine derivatives;
  • acute stage myocardial infarction (first 4 weeks);
  • cardiogenic shock, collapse;
  • arterial hypotension (systolic blood pressure below 90 mmHg);
  • weakness syndrome sinus node;
  • heart failure (in the stage of decompensation);
  • severe aortic stenosis;
  • severe mitral stenosis;
  • tachycardia;
  • idiopathic hypertrophic subaortic stenosis;
  • pregnancy, lactation period;
  • age under 18 years (efficacy and safety have not been established).

  • Use with caution in patients:
    with chronic heart failure, severe liver and/or kidney dysfunction; severe violations cerebral circulation, diabetes mellitus, malignant arterial hypertension, patients on hemodialysis (due to the risk of arterial hypotension).

    Directions for use and doses

    The dosage regimen is set individually, depending on the severity of the disease and the patient’s response to the therapy. It is recommended to take the drug during or after meals, without pouring big amount water. Initial dose: 1 tablet (10 mg) 2-3 times a day. If necessary, the dose of the drug can be increased to 2 tablets (20 mg) 1-2 times a day. The maximum daily dose is 40 mg. In elderly patients or patients receiving combination (antianginal or antihypertensive) therapy, as well as in cases of impaired liver function, in patients with severe cerebrovascular accidents, the dose should be reduced.

    Side effects

    From the outside of cardio-vascular system: facial hyperemia, feeling of heat, tachycardia, peripheral edema (ankles, feet, legs), excessive decrease in blood pressure (BP), syncope, heart failure; in some patients, especially at the beginning of treatment, angina attacks may occur, which requires discontinuation of the drug.
    From the nervous system: headache, dizziness, increased fatigue, drowsiness. With prolonged oral administration in high doses - paresthesia of the limbs, tremor.
    From the gastrointestinal tract, liver: dyspeptic disorders (nausea, diarrhea or constipation), with long-term use - liver dysfunction (intrahepatic cholestasis, increased activity of liver transaminases).
    From the musculoskeletal system: arthritis, myalgia.
    Allergic reactions: skin itching, urticaria, exanthema, autoimmune hepatitis.
    From the hematopoietic organs: anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura.
    From the urinary system: increase in daily diuresis, deterioration of kidney function (in patients with renal failure).
    Other:"flushes" of blood to the skin of the face, changes in visual perception, gynecomastia (in elderly patients, completely disappearing after withdrawal), hyperglycemia, gum hyperplasia.
    Overdose
    Symptoms: headache, flushing of the facial skin, decreased blood pressure, depression of the sinus node, bradycardia, arrhythmia.
    Treatment: gastric lavage with prescription activated carbon, symptomatic therapy, aimed at stabilizing the activity of the cardiovascular system. The antidote is calcium; slow intravenous administration of 10% calcium chloride or calcium gluconate is indicated, followed by switching to a long-term infusion.
    With a pronounced decrease in blood pressure, intravenous administration of dopamine or dobutamine. In case of conduction disturbances, the administration of atropine, isoprenaline or the installation of an artificial pacemaker is indicated. With the development of heart failure -intravenous administration strophanthin. Catecholamines should only be used in cases of circulatory failure, life threatening(due to their reduced efficiency, it is required high dosage, as a result of which the danger of increasing the tendency to arrhythmia due to intoxication increases). It is recommended to control blood glucose and electrolytes (potassium and calcium ions), as insulin release is impaired.
    Hemodialysis is ineffective.

    Interaction with other drugs

    The severity of the decrease in blood pressure increases with the simultaneous administration of nifedigestion with other antihypertensive drugs, cimetidine, ranitidine, diuretics and tricyclic antidepressants.
    In combination with nitrates, tachycardia and the hypotensive effect of nifedish are enhanced.
    The simultaneous administration of beta-blockers must be carried out under conditions of careful medical supervision, since this may cause an excessive decrease in blood pressure, and in some cases, aggravation of symptoms of heart failure.
    Cordaflex reduces the concentration of quinidine in the blood plasma. Increases the concentration of digoxin and theophylpine in the blood plasma, and therefore the clinical effect and/or the content of digoxin and theophylline in the blood plasma should be monitored.
    Rifampicin weakens the effect of nifedipine (accelerates the metabolism of the latter due to the induction of liver enzyme activity).
    special instructions
    During the treatment period, it is necessary to refrain from potentially active activities dangerous species activities requiring increased concentration attention and speed of psychomotor reactions, and from the use of ethanol.
    The drug is discontinued gradually (risk of developing withdrawal syndrome).

    Release form

    Dragee 10 mg.
    10 tablets per blister made of PVC and aluminum foil.
    5 blisters of 10 tablets each, along with instructions for use, are placed in a cardboard box.

    Storage conditions

    List B. In a dry place, protected from light and out of reach of children, at a temperature not exceeding 25° C.

    Best before date

    3 years. Do not use too late indicated on the packaging.

    Vacation conditions

    On prescription.

    Manufacturer:


    Balkanfarma-Dupnitsa AD,
    2600 Dupnitsa, Bulgaria, st. "Samokovskoye Highway" 3

    The information on the page was verified by physician-therapist E.I. Vasilyeva.

    Cordaflex is a complex antihypertensive and antianginal drug that helps to effectively cope with high blood pressure.

    After internal reception given medication there is a fairly rapid expansion of coronary and peripheral blood vessels, which can effectively reduce high blood pressure.

    Main operating medicinal substance Cordaflexa is Nifedipine, which has pronounced antihypertensive properties.

    After internal administration, the hypotensive effect, as a rule, develops within 20-25 minutes. and continues for 12-24 hours.

    Most often, this drug is well tolerated by patients of all ages.

    Main indications for use of Cordaflex:

    • IHD (coronary heart disease);
    • Raynaud's syndrome;
    • angina ( painful sensations in the area of ​​the heart).

    Attention: Before starting to use Cordaflex, it is recommended to consult with a qualified cardiologist or therapist!

    The drug is available in the form of soluble tablets for internal use.

    How to drink Cordaflex?

    The initial daily dose of this medicinal product is 1 t. (10 mg.) 2-3 r. the day before meals, drinking sufficient quantity water. The minimum interval between doses of Cordaflex should be 2-3 hours.

    The course of treatment and dose of the drug is selected by the attending physician absolutely individually for each patient, depending on the severity of the particular disease.

    The maximum daily dose of the drug should not exceed more than 4 tons (40 mg) as this may adversely affect general condition body.

    For elderly patients, an initial daily dose of 5 mg is recommended. (1/2 t.) 2-3 r. per day, preferably 15-20 minutes. before meals, drink plenty of water.

    Contraindications to the use of Cordaflex

    • hypersensitivity (increased sensitivity of the body to the main active ingredients of the drug);
    • age under 18 years;
    • arterial hypotension (low blood pressure);
    • cardiogenic shock;
    • severe heart failure;
    • pregnancy and lactation (breastfeeding);
    • acute myocardial infarction;
    • tachycardia (rapid heartbeat).

    Side effects of Cordaflex

    • headache;
    • severe arterial hypotension;
    • periodic dizziness;
    • sleep disturbance (insomnia);
    • indigestion (
    Arena Pharmaceuticals GmbH/Egis pharmaceutical plant for Arena Pharmaceuticals GmbH/Egis pharmaceutical plant JSC Siegfried Ltd Egis JSC pharmaceutical plant Egis pharmaceutical plant JSC Egis Pharmaceutical plant JSC Egis Pharmaceutical plant JSC

    Country of origin

    Hungary Hungary/Switzerland Switzerland Switzerland/Hungary

    Product group

    Cardiovascular drugs

    Calcium channel blocker

    Release forms

    • 30 or 60 tablets in brown glass bottles, sealed with polyethylene caps with first opening control and equipped with an accordion shock absorber. 1 bottle along with instructions for use is packed in a cardboard box. 30 tablets in brown glass bottles, sealed with polyethylene caps with first opening control and equipped with an accordion shock absorber. 1 bottle along with instructions for use is packed in a cardboard box. Controlled-release film-coated tablets 40 mg. 10 tablets in a blister made of PVC/PVDC/alfoil. 1 or 3 blisters in a cardboard box along with instructions for use. Film-coated tablets, 10 mg. 100 tablets in a brown glass bottle. 1 bottle is placed in a cardboard box along with instructions for use.

    Description of the dosage form

    • : round, biconvex, film-coated tablets, brownish-red in color, beveled, odorless. biconvex round tablets, film-coated, brownish purple with a matte or slightly shiny surface. Odorless or with a weak characteristic odor. Broken appearance: yellow along the edges with a narrow stripe of brownish-violet color. Biconvex round tablets, coated with a matte or slightly shiny coating, yellow in color, with a slight characteristic odor.

    pharmachologic effect

    The active ingredient of the drug Cordaflex® RD is nifedipine. Nifedipine is a selective blocker of “slow” calcium channels, a 1,4-dihydropyridine derivative. Has antihypertensive and antianginal effects. Reduces the flow of extracellular calcium ions into cardiomyocytes and smooth muscle cells of the coronary and peripheral arteries. In therapeutic doses, it normalizes the transmembrane current of calcium ions, which is disturbed in a number of pathological conditions, primarily arterial hypertension. Reduces spasm and dilates coronary and peripheral arterial vessels, reduces total peripheral resistance, reduces afterload and myocardial oxygen demand. At the same time, it improves blood supply to ischemic areas of the myocardium without developing the “steal” syndrome, and also activates the functioning of collaterals. It has virtually no effect on the sinoatrial and atrioventricular nodes and does not have either pro- or antiarrhythmic effects. Does not affect the tone of the veins. Nifedipine increases renal blood flow, causing moderate natriuresis. In high doses, it inhibits the release of calcium ions from intracellular stores. Reduces the number of functioning calcium channels without affecting the time of their activation, inactivation and recovery.

    Pharmacokinetics

    Absorption Nifedipine is rapidly and almost completely (90%) absorbed from the gastrointestinal tract after oral administration. The duration of the effect after a single oral dose exceeds 24 hours. When developing the active substance of the drug Cordaflex® RD, zero-order release kinetics was chosen in order to ensure a constant release rate. The relative bioavailability of the drug is about 60%. The maximum concentration (Cmax) in blood plasma is 29.4 ± 12.0 mg/ml (x ± SD); the concentration of the drug in the blood plasma reaches a plateau 7.4 ± 6.4 hours after taking each dose. Maximum levels of the drug in blood plasma are achieved when it is taken in combination with food. However, at the end of the dosing interval, the concentration of the drug in the blood plasma does not change. Distribution: The connection with blood plasma proteins (albumin) is 94-97%. Studies with labeled nifedipine in animals have shown that unbound nifedipine is distributed in all organs and tissues. Nifedipine concentrations were found to be higher in the myocardium than in skeletal muscles. There is no cumulative effect. Metabolism Nifedipine is mainly metabolized in the liver to inactive metabolites. Excretion 60-80% of the drug dose taken orally is excreted in the urine in the form of inactive metabolites, the remaining part is excreted in bile and feces. The half-life of nifedipine from blood plasma is approximately 2 hours. However, the release of the drug Cordaflex®RD is longer - up to 14.9 ± 6.0 hours in the equilibrium concentration phase. The concentration of the drug in the blood plasma reaches a minimum of 12.0±6.5 ng/ml 24 hours after administration, which is twice the concentration achieved after taking 20 mg of nifedipine 2 times a day. If renal function is impaired, the pharmacokinetics of nifedipine does not change (nifedipine is excreted in the urine in small quantities). With a significant decrease in liver function, the clearance of nifedipine is reduced, so it is not recommended to exceed daily dose.

    Special conditions

    Do not take to relieve an attack of angina! Extra Caution necessary when prescribing Cordaflex® to patients with significant arterial hypotension (systolic blood pressure below 90 mm Hg). The antihypertensive effect of Cordaflex® is enhanced by hypovolemia. For kidney disease, the dose of nifedipine does not need to be specified. Reduced pressure in pulmonary artery and hypovolemia after dialysis may enhance the effects of Cordaflex®, and therefore a dose reduction is recommended. Despite the absence of withdrawal syndrome with Cordaflex®, a gradual dose reduction is recommended before stopping treatment. Importance has regularity of treatment regardless of health, since the patient may not feel the symptoms of arterial hypertension. The simultaneous administration of beta-blockers must be carried out under conditions of careful medical supervision, since this may cause an excessive decrease in blood pressure, and in some cases, aggravation of heart failure. It is not recommended to simultaneously administer IV therapy with beta-adrenergic blockers and intracoronary administration of nifedipine. During treatment it is possible positive results when performing direct Coombs reaction and laboratory tests for antinuclear antibodies. If during therapy the patient requires surgical intervention under general anesthesia, it is necessary to inform the anesthesiologist about the nature of the therapy being performed. Caution should be exercised in elderly patients due to most likely age-related renal dysfunction. Caution is required when using Cordaflex® in patients with liver disease. At portal hypertension and cirrhosis, the dose should be reduced. In rare cases, chest pain (angina due to paradoxical ischemia) may occur at the beginning of a course of treatment with nifedipine or when its dose is increased soon after taking the drug. When found causation Between taking Cordaflex® and angina pectoris, the drug should be discontinued. Patients with diabetes mellitus require careful medical supervision while taking Cordaflex®. During the course of treatment with the drug, you should avoid drinking alcohol. Each tablet contains 30 mg of lactose monohydrate. This drug should not be prescribed to patients with lactase deficiency, lactose intolerance, or glucose-galactose malabsorption. Effect on ability to drive vehicles During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Overdose: In addition to the side effects listed above, you may experience following symptoms, depending on the severity of intoxication: marked decrease in blood pressure, tachycardia, chest pain, fainting and loss of consciousness due to heart rhythm disturbances: depression of the sinus node, bradycardia, prolongation of AV conduction, ventricular extrasystole; inhibition of insulin secretion. In more severe cases– confusion may occur, leading to coma, hyperkalemia, metabolic acidosis, hypoxia and cardiogenic shock with pulmonary edema. Treatment of overdose: There is no specific antidote for an overdose of nifedipine, therefore, first of all, measures should be taken to eliminate nifedipine and maintain the function of the cardiovascular system. In case of overdose, as first therapeutic event gastric lavage and activated charcoal should be taken; if necessary, with colon lavage. Complete removal of unabsorbed nifedipine by gastric and colon lavage is especially important in cases of overdose with extended-release drugs to prevent further absorption. Laxatives can be prescribed, however, in the case of blockers of “slow” calcium channels, inhibition of intestinal motility up to atony should be taken into account. Nifedipine is not excreted by dialysis, therefore, hemodialysis is ineffective, however, plasmapheresis is recommended (given the high percentage of nifedipine binding to plasma proteins and the relatively small volume of distribution). As symptomatic treatment bradycardia, atropine and/or beta-agonists can be prescribed. For life-threatening bradycardia, a temporary pacemaker should be installed. With a pronounced decrease in blood pressure due to cardiogenic shock and vasodilation of the arteries, calcium (1-2 g of calcium gluconate intravenously), dopamine (maximum 25 mcg/kg body weight/min), dobutamine (maximum 15 mcg/kg body weight/min) and epinephrine or norepinephrine. The dose of these drugs should be determined according to response patients. Serum calcium may be normal or slightly elevated. Additional fluid administration should be done with caution under the control of hemodynamic parameters to prevent cardiac overload.

    Compound

    • 1 tablet contains: active ingredient - nifedipine 20 mg, Excipients: tablet core: microcrystalline cellulose 99 mg, lactose monohydrate 30 mg, croscarmellose sodium 26 mg, methyl methacrylate and ethyl acrylate copolymer 1.9 mg, talc 2 mg, magnesium stearate 0.6 mg, hyprolose 0.5 mg; tablet shell: hypromellose 5.26 mg, titanium dioxide 1.64 mg, red iron oxide dye (E 172) 0.6 mg, magnesium stearate 0.5 mg. : 1 tablet contains 40 mg of the active substance - nifedipine, as well as excipients: cellulose, microcrystalline cellulose, lactose, hypromellose 4000, magnesium stearate, colloidal anhydrous silicon dioxide. The tablet shell contains: hypromellose 15, macrogol 6000, macrogol 400, red iron oxide E 172, titanium dioxide E 171, talc. : 1 tablet contains: active ingredient - nifedipine 20 mg, excipients: tablet core: microcrystalline cellulose 99 mg, lactose monohydrate 30 mg, croscarmellose sodium 26 mg, methyl methacrylate and ethyl acrylate copolymer 1.9 mg, talc 2 mg, magnesium stearate 0, 6 mg, hyprolose 0.5 mg; tablet shell: hypromellose 5.26 mg, titanium dioxide 1.64 mg, red iron oxide dye (E 172) 0.6 mg, magnesium stearate 0.5 mg. Each film-coated tablet contains active substance: nifedipine 10 mg, as well as excipients: polyvinyl butyral, magnesium stearate, talc, hydroxypropyl cellulose, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, titanium dioxide, yellow iron oxide, hypromellose.

    Cordaflex indications for use

    Cordaflex contraindications

    • - acute stage of myocardial infarction; - cardiogenic shock; - severe arterial hypotension (systolic blood pressure below 90 mm Hg); - severe aortic or mitral stenosis, idiopathic hypertrophic subaortic stenosis; - severe heart failure; - I trimester of pregnancy; - lactation period ( breastfeeding); - children's and adolescence up to 18 years old; - hypersensitivity to nifedipine and other components of the drug. Cordaflex® should be used with caution in chronic heart failure, hypertrophic obstructive cardiomyopathy, severe cerebrovascular accidents, CVS, severe tachycardia, severe liver and/or kidney dysfunction, malignant arterial hypertension, in patients on hemodialysis (due to the risk the occurrence of severe arterial hypotension against the background of peripheral vasodilation), with lactose intolerance, as well as in elderly patients.

    Cordaflex dosage

    • 10 mg 10 mg, 5 mg 20 mg 20 mg 40 mg

    Cordaflex side effects

    • The frequency of side effects is adjusted to the following categories: very common (? 1/10); often (?1/100 -

    Drug interactions

    Rifampicin is a powerful inducer of the CYP3A4 isoenzyme. At simultaneous use with rifampicin, the bioavailability of nifedipine is significantly reduced and, accordingly, its effectiveness is reduced. The use of nifedipine in combination with rifampicin is contraindicated (see section "Contraindications"). Since rifampicin and phenytoin - through enzyme induction - significantly reduce the plasma level of nifedipine, it cannot be excluded similar action barbiturates and carbamazepine. When taken simultaneously with other antihypertensive drugs ( ACE inhibitors, diuretics, etc.), nitrates, psychotropic drugs and drugs containing magnesium may enhance the hypotensive effect. Simultaneous use with beta-blockers enhances the hypotensive and antianginal effects, which is generally beneficial; however, the use of such a combination of drugs requires special caution due to the possibility of an excessive decrease in blood pressure, the development of arterial hypotension and heart failure. When used together with prazosin, severe orthostatic hypotension. Concomitant use nifedipine with digoxin may lead to increased plasma concentrations of digoxin. When used simultaneously with theophylline, the concentration of theophylline in plasma may increase. The use of nifedipine simultaneously with quinidine requires special caution, since when taken simultaneously, the plasma concentration of quinidine may decrease, and when nifedipine is discontinued, it may increase: simultaneous use of these drugs can lead to malignant ventricular arrhythmia (pathological increase in the QT interval on the ECG). Diltiazem increases plasma concentrations of nifedipine. Nifedipine may increase the anticoagulant effect of coumarin derivatives. Since nifedipine is metabolized with the participation of the CYP3A4 isoenzyme, any inhibitor or inducer of this enzyme can alter the metabolism of nifedipine: Grapefruit juice, erythromycin, antifungal drugs from the azole group (for example, ketoconazole), some fluoroquinolones, norfloxacin, ciprofloxacin, oral contraceptives containing progestogen, and HIV protease inhibitors (for example, indinavir, ritonavir) can inhibit the metabolism of nifedipine and increase its effect. Similarly, concomitant use of nifedipine and cimetidine increases its plasma concentration and thus the effect of nifedipine, however joint reception Ranitidine does not lead to a significant increase in plasma nifedipine levels. Cyclosporine is also a substrate for the CYP3A4 isoenzyme, therefore, when taken simultaneously, the duration of action of both drugs may increase. Simultaneous use nifedipine with weak and moderate inhibitors of the CYP3A4 isoenzyme requires regular monitoring of blood pressure and, if necessary, a reduction in the dose of nifedipine. These drugs include: macrolide antibiotics (azithromycin, which belongs to the macrolide group, is not an inhibitor of the CYP3A4 isoenzyme). Nifedipine reduces the excretion of vincristine, thereby increasing its side effects. The need to reduce the dose of vincristine should be considered. Concomitant use of cisapride and nifedipine may lead to an increase in the concentration of nifedipine in the blood plasma. Blood pressure should be monitored and, if necessary, the dose of nifedipine should be reduced. Concomitant use of quinupristin/dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine. Blood pressure should be monitored and, if necessary, the dose of nifedipine should be reduced. Clinical researches There were no interactions between nifedipine and valproic acid. Since it has been shown that valproic acid increases the concentration in the blood plasma of nimodipine, which is structurally similar to nifedipine, due to inhibition of microsomal liver enzymes, then the possibility of an increase in the concentration of nifedipine in the blood plasma cannot be excluded. The following drugs do not affect the pharmacokinetics of nifedipine: ajmaline, benazepril, debrisoquine, doxazosin, irbesartan, omeprazole, orlistat, pantoprazole, ranitidine, rosiglitazone, talinolol, triamterene/hydrochlorothiazide, acetylsalicylic acid and candesartan